0938 GMT - Haleon's results were notably poor in respiratory health, says RBC's James Edwardes Jones in a note. Respiratory results were prompted by a double-digit revenue decline in APAC, notably China, he adds. However, this was somewhat offset by areas like pain relief and digestive health, he adds. Overall, North America came in slightly ahead, while other regions were a bit weaker, he adds. Shares are down 0.7% at 377.10 pence.